80896-73-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-4-phenyl-pyrrolidine-3-carboxylic acid is used as a potential therapeutic agent for the treatment of neurodegenerative diseases and psychiatric disorders. Its interaction with the σ1 receptor suggests that it may have neuroprotective and neurorestorative properties, making it a promising candidate for conditions such as Alzheimer's disease, Parkinson's disease, and depression.
Used in Pain Management:
BPPCA is used as a potential analgesic agent for the management of chronic and acute pain. Its interaction with the σ1 receptor may contribute to its pain-relieving effects, offering a new avenue for the development of pain management therapies.
Used in Drug Addiction Treatment:
1-Benzyl-4-phenyl-pyrrolidine-3-carboxylic acid is used as a potential treatment for drug addiction. Its interaction with the σ1 receptor may help in reducing cravings and withdrawal symptoms associated with drug addiction, providing a new approach to addiction treatment and recovery.

InChI:InChI=1/C18H19NO2/c20-18(21)17-13-19(11-14-7-3-1-4-8-14)12-16(17)15-9-5-2-6-10-15/h1-10,16-17H,11-13H2,(H,20,21)

Upstream product

• 6273-59-2 2-(benzylamino)-2-phenylethanol 
• 951742-95-3 1-benzyl-4-phenyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid 
• 438492-33-2 (3R,4S)-methyl 1-benzyl-4-phenylpyrrolidine-3-carboxylate 
• 103-36-6 ethyl 3-phenyl-2-propenoate 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 80896-26-0 3-propionitrile 
• 70-11-1 α-bromoacetophenone 
• 706-03-6 3-(benzylamino)propionitrile 
• 1201574-98-2 3-{benzyl[(2R)-2-chloro-2-phenylethyl]amino}propanenitrile 
• 20780-53-4 (R)-Styrene oxide 
• 80896-11-3 3-(N-benzyl-N-phenacylamino)propionitrile 
• 98-80-6 phenylboronic acid 
• 80896-16-8 3-propionitrile 
• 698358-08-6 tert-butyl 1-(phenylmethyl)-2,5-dihydropyrrole-3-carboxylate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

NOVEL METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUND

[Object] A novel method for producing an optically active pyrrolidine compound, which is useful as a production intermediate of a pharmaceutical, and a production intermediate thereof, is provided. [Means for Solution] According to the production method o

A practical and efficient synthesis of (3R,4S)-1-benzyl-4- phenylpyrrolidine-3- carboxylic acid via an aziridinium ion intermediate

A practical and efficient synthesis of (3R,4S)-1-benzyl4-phenylpyr- rolidine-3-carboxylic acid (1), a key chiral building block for synthesis of biologically active compounds was established by utilizing a stereospecific and regioselective chlorination of in situ generated aziridinium ion, followed by a nitrile anion cyclization. Starting from commercially available (R)-styrene oxide and 3-(benzylamino)propionitrile, the four-step synthesis features a through process without purification of intermediates until isolation of crystalline 1. The robust, chromatography-free and reproducible synthesis of 1 achieved an 84% overall yield from (R)-styrene oxide. This highly efficient process was successfully demonstrated at pilot scale with 17 kg output of 1.

Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids

The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme w

Tricyclic indanyls as integrin inhibitors

The present invention is directed to substituted indanyl compounds of Formula (I): Useful for treating integrin-mediated disorders such as, but not limited to unstable angina, thromboemboic disorders, osteoporosis, growth and metastasis of malignant tumors, diabetic retinopathy, arthritis, viral disease and surgical adhesions.

A rapid catalytic asymmetric synthesis of 1,3,4-trisubstituted pyrrolidines

The asymmetric synthesis of 1,3,4-trisubstituted pyrrolidines was accomplished in two steps from readily available starting materials. A 1,3-dipolar cycloaddition of an azomethine ylide to a propiolate ester followed by a Rh-catalyzed asymmetric 1,4-arylation of the resulting pyrroline with an arylboronic acid provided the desired 1,3,4-trisubstituted pyrrolidine products in good to excellent enantioselectivities.

Synthesis of Phenyl- and Benzyl-Substituted Pyrrolidines and of a Piperidine by Intramolecular C-Alkylation. Synthons for Tricyclic Skeletons

The construction of new or novelly functionalized annulated and bridged tricyclic compounds by two consecutive C,C-bond formations (a and b in 1a, Scheme 1) is described.In a first step, Chloroalkyl-substituted aminonitriles yielded pyrrolidines 8, 15a, 1